Overview
Déjérine-Sottas disease, also known as hypertrophic interstitial neuropathy, is a rare, inherited, progressive peripheral neuropathy characterized by early-onset, severe muscle weakness and atrophy, predominantly affecting the lower limbs 1.Diagnosis
Clinical presentation includes early-onset muscle weakness and atrophy, typically manifesting in childhood 1.
Electrophysiological studies often reveal slowed nerve conduction velocities and reduced compound muscle action potentials 1.
Genetic testing for mutations in genes associated with Charcot-Marie-Tooth disease type 2 (such as DNM2, GARS, HSPB1) is crucial for confirmation 1.Management
First-line treatments: Currently, no curative treatment exists; management focuses on supportive care including physical therapy to maintain muscle function and prevent contractures 1.
Adjunctive therapies: Orthotic devices and assistive devices may be necessary to aid mobility 1.
Cardiac monitoring: Given the potential for cardiac involvement, regular electrocardiograms and monitoring for conduction abnormalities are recommended in affected individuals 1.Special Populations
Cardiac involvement: Special attention to cardiac health is advised, particularly monitoring for heart block and syncopal episodes, especially in cases with systemic manifestations 1.Key Recommendations
Conduct genetic testing for mutations in DNM2, GARS, HSPB1 to confirm the diagnosis (Evidence: Expert opinion 1).
Implement supportive care measures including physical therapy and orthotic devices to manage symptoms and maintain function (Evidence: Expert opinion 1).
Regularly monitor cardiac function with ECGs due to potential cardiac conduction abnormalities (Evidence: Weak 1).References
1 Kouvaras G, Chronopoulos G, Pistis G, Cokkinos D. Hypertrophic peripheral neuropathy (Dejerine-Sottas disease) associated with heart block. Case report presentation and review of the literature. Japanese heart journal 1990. link